Scarica l'app Stockscreener
59.02
0.17%
0.10
Dopo l'orario di chiusura:
59.02
Vaxcyte Inc Borsa (PCVX) Ultime notizie
Trading the Move, Not the Narrative: (PCVX) Edition - Stock Traders Daily
Vaxcyte EVP Jim Wassil sells $163,862 in company stock By Investing.com - Investing.com South Africa
Vaxcyte CFO Andrew Guggenhime Forfeits 7,155 Shares, 7% of Holdings at $60.36 Each - Kalkine Media
Vaxcyte EVP Jim Wassil sells $163,862 in company stock - Investing.com
Vaxcyte (PCVX) officer plans stock sale after RSU vest - Stock Titan
Vaxcyte at Cantor conference: broad vaccine bet nears key test By Investing.com - Investing.com Canada
PCVX: VAX-31 phase III data expected by end of October, targeting broader pneumococcal protection - TradingView
Vaxcyte at Wells Fargo conference: broader vaccines, bigger stakes By Investing.com - Investing.com Nigeria
Why Are Vaxcyte (NASDAQ:PCVX) Shares Under Pressure After A Timeline Update? - Kalkine Media
Vaxcyte Executive Sells Shares for Tax Obligations - Intellectia AI
Vaxcyte Has $2.5 Billion in Cash and a $605 Million Half-Year Loss. Here's How to Read Its CFO's Latest Insider Filing - The Motley Fool
A Vaxcyte Executive Just Cashed Options Struck at $5.35. Here's What Long-Term Investors Should Know - The Globe and Mail
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte's CEO Parted With Shares for Taxes. Here's What Long-Term Investors Should Know About the Firm - The Motley Fool
Vaxcyte (PCVX) Stock Price, News & Analysis - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: Examining a Potential 78% Upside in the Biotech Frontier - DirectorsTalk Interviews
Vaxcyte (PCVX) Sets Phase 3 Pneumococcal Vaccine Data Release, M - GuruFocus
Vaxcyte narrows timing for pivotal VAX-31 data to late October (PCVX:NASDAQ) - Seeking Alpha
The Next Year Will Define Vaxcyte’s (PCVX) Vaccine Gamble - Yahoo Finance
Leadership Hires and OPUS-1 Timeline Could Be A Game Changer For Vaxcyte (PCVX) - simplywall.st
Vaxcyte Stock Price Forecast. Should You Buy PCVX? - StockInvest.us
Vaxcyte Appoints New Chief Medical Officer, Updates Trial Timeline - The Globe and Mail
Vaxcyte (NASDAQ: PCVX) officer plans new stock sale after recent trades - Stock Titan
Vaxcyte Inc. (PCVX) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
Vaxcyte stock jumps on new executives, VAX-31 data timeline - investing.com
Vaxcyte stock jumps on new executives, VAX-31 data timeline By Investing.com - Investing.com Australia
Vaxcyte Appoints Chief Medical Officer And Chief Legal Officer Narrows Guidance For Expected Vax-31 Opus-1 Topline Data - TradingView
Vaxcyte appoints two executives, narrows trial timeline By Investing.com - Investing.com Canada
Vaxcyte Inc (PCVX) Updates Phase 3 Trial Timeline, Market Pricin - GuruFocus
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data - Investing News Network
Vaxcyte appoints two executives, narrows trial timeline - investing.com
Vaxcyte, Inc. Announces Management Changes - marketscreener.com
Vaxcyte COO Jim Wassil sells over $212,000 in company stock By Investing.com - Investing.com South Africa
Vaxcyte Appoints Chief Medical Officer and Chief Legal - GlobeNewswire
Vaxcyte COO Jim Wassil sells over $212,000 in company stock - investing.com
(PCVX) Movement as an Input in Quant Signal Sets - news.stocktradersdaily.com
Vaxcyte Options Spot-On: On September 1st, 90,099 Contracts Were Traded, With 97,138 Open Interest - Moomoo
Vaxcyte (NASDAQ: PCVX) officer lines up new stock sale after recent trades - Stock Titan
Vaxcyte, Inc. (PCVX) Investor Outlook: Biotech Stock With An 82% Potential Upside - DirectorsTalk Interviews
Vaxcyte Inc. (PCVX) Key Financial Ratios – Valuation, Profitability & More - Value Research
Vaxcyte Inc. (PCVX) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
Vaxcyte (PCVX) Pulls Back 2.2% to $59.84, Approaches Key Support at $56.85Volume Gap - vinanet.vn
Vaxcyte to Participate in Upcoming Investor Conferences - manilatimes.net
0.14%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):